



10-18-04

1623 #

gte 10/15/04 4239-61997-01 318644.doc
E-147-99/2

PATENT
Attorney Reference Number 4239-61997-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klinman et al.

Application No. 10/068,160

Filed: February 6, 2002

Confirmation No. 9731

For: OLIGODEOXYNUCLEOTIDE AND ITS
USE TO INDUCE AN IMMUNE
RESPONSE

Examiner: Dave Nguyen

Art Unit: 1623

Attorney Reference No. 4239-61997-01

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label Nos. EV514604932US, EV514604-946US, and EV514604950US in three boxes addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed October 15, 2004

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Supplemental Information Disclosure Statement
 - ☒ Form 1449
 - ☒ IDS Fee of \$180.00
- ☒ The references listed on the Form 1449 are enclosed in three separate boxes, each with a separate Express Mail Label. Copies of the Supplemental Information Disclosure Statement and the Form 1449 are enclosed in each box.
- ☒ A check in the amount of \$180.00 is enclosed in Box 1 of 3 to cover the IDS fee.
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.


cc: Docketing

☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



10/15/04 4239-61997-01 318643.doc

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klinman et al.

Application No. 10/068,160

Filed: February 6, 2002

Confirmation No. 9731

For: OLIGODEOXYNUCLEOTIDE AND ITS
USE TO INDUCE AN IMMUNE
RESPONSE

Examiner: Dave Nguyen

Art Unit: 1623

Attorney Reference No. 4239-61997-01

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label Nos. EV514604932US, EV514604-946US, and EV514604950US in three boxes addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed October 15, 2004

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal sheet for this IDS is enclosed.

10/20/2004 SSANDARA 00000014 10068160

01 FC:1806


180.00 DP

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen


U.S. PATENT DOCUMENTS

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
	P-1	2,215,233	9/17/1940	Ruskin
	P-2	3,906,092	9/16/1975	Hilleman, et al.
	P-3	3,911,117	10/7/1975	Ender
	P-4	3,914,450	10/21/1975	Robbins, et al.
	P-6	4,544,559	10/1/1985	Gil, et al.
	P-7	4,741,914	5/3/1988	Kimizuka, et al.
	P-8	4,758,553	7/19/1988	Ogoshi
	P-9	4,806,376	2/21/1989	Saeki, et al.
	P-10	4,956,296	9/11/1990	Fahnestock
	P-11	4,963,387	10/16/1990	Nakagawa, et al.
	P-12	4,994,442	2/19/1991	Gil, et al.
	P-14	5,066,500	11/19/1991	Gil, et al.
	P-15	5,231,085	7/27/1993	Alexander, et al.
	P-16	5,234,811	8/10/1993	Beutler, et al.
	P-17	5,248,670	9/28/1993	Draper, et al.
	P-18	5,268,365	12/7/1993	Rudolph, et al.

References in Box 1 of 3

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

P-19	5,288,509	2/22/1994	Potman, et al.
P-20	5,488,039	1/30/1996	Masor, et al.
P-21	5,492,899	2/20/1996	Masor, et al.
P-22	5,585,479	12/17/1996	Hoke, et al.
P-23	5,591,721	1/7/1997	Agrawal, et al.
P-24	5,602,109	2/11/1997	Masor, et al.
P-25	5,612,060	3/18/1997	Alexander
P-26	5,614,191	3/25/1997	Puri, et al.
P-27	5,650,156	7/22/1997	Grinstaff, et al.
P-29	5,679,397	10/21/1997	Kuroda, et al.
P-30	5,684,147	11/4/1997	Agrawal, et al.
P-31	5,700,590	12/23/1997	Masor, et al.
P-32	5,712,256	1/27/1998	Kulkarni, et al.
P-33	5,723,335	3/3/1998	Hutcerson, et al.
P-34	5,786,189	7/28/1998	Loct, et al.
P-35	5,804,566	9/8/1998	Carson, et al.
P-36	5,840,705	11/24/1998	Tsukuda
P-37	5,849,719	12/15/1998	Carson, et al.
P-38	5,895,652	4/20/1999	Giampapa

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

P-39	5,919,456	7/6/1999	Puri, et al.
P-40	5,922,766	7/13/1999	Acosta, et al.
P-41	5,976,580	11/2/1999	Ivey, et al.
P-42	5,980,958	11/9/1999	Naylor, et al.
P-43	5,994,126	11/30/1999	Stienman, et al.
P-44	6,008,200	12/28/1999	WITHDRAWN
P-45	6,022,853	2/8/2000	Kuberasampath, et al.
P-46	6,194,388	2/27/2001	Krieg, et al.
P-48	6,214,806	4/10/2001	Krieg, et al.
P-49	6,218,371	4/17/2001	Krieg, et al.
P-50	6,239,116	5/29/2001	Krieg, et al.
P-51	6,339,068	1/15/2002	Krieg, et al.
P-52	6,406,705	6/18/2002	Davis, et al.
P-53	6,423,539	7/23/2002	Fong, et al.
P-54	6,428,788	8/6/2002	Debinski, et al.
P-55	6,429,199	8/6/2002	Krieg, et al.
P-56	6,498,148	12/24/2002	Raz
P-57	6,514,948	2/4/2003	Raz, et al.
P-58	6,534,062	3/18/2003	Krieg, et al.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

	P-59	6,552,006	4/22/2003	Raz, et al.
	P-60	6,562,798	5/13/2003	Schwartz
	P-61	6,589,940	7/8/2003	Raz, et al.
	P-62	6,610,661	8/26/2003	Carson, et al.
	P-63	6,613,751	9/2/2003	Raz, et al.
	P-64	6,653,292	11/25/2003	Krieg, et al.
	A-1	2001-0034330	10/25/2001	Kensil
	A-2	2001-0036462	11/1/2001	Fong, et al.
	A-3	2001-0044416	11/22/2001	McCluskie, et al.
	A-4	2001-0046967	11/29/2001	Van Nest
	A-5	2002-0006403	1/17/2002	Yu, et al.
	A-6	2002-0028784	3/7/2002	Van Nest
	A-7	2002-0042383	4/11/2002	Yew, et al.
	A-8	2002-0042387	4/11/2002	Raz, et al.
	A-9	2002-0055477	5/9/2002	Van Nest, et al.
	A-10	2002-0064515	5/30/2002	Krieg, et al.
	A-11	2002-0065236	5/30/2002	Yew, et al.
	A-12	2002-0086295	7/4/2002	Raz, et al.
	A-13	2002-0086839	7/4/2002	Raz, et al.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.


**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

	A-14	2002-0090724	7/11/2002	Taylor, et al.
	A-15	2002-0091095	7/11/2002	Phillips, et al.
	A-16	2002-0091097	7/11/2002	Bratzler, et al.
	A-17	2002-0098199	7/25/2002	Van Nest, et al.
	A-18	2002-0098205	7/25/2002	Choi, et al.
	A-19	2002-0098980	7/25/2002	Choi, et al.
	A-20	2002-0107212	8/8/2002	Van Nest, et al.
	A-21	2002-0110569	8/15/2002	Granoff, et al.
	A-22	2002-0111323	8/15/2002	Martin, et al.
	A-23	2002-0136776	9/26/2002	Fang, et al.
	A-24	2002-0137714	9/26/2002	Kandimalla, et al.
	A-25	2002-0142974	10/3/2002	Kohn, et al.
	A-26	2002-0142977	10/3/2002	Raz, et al.
	A-27	2002-0142978	10/3/2002	Raz, et al.
	A-28	2002-0156033	10/24/2002	Bratzler, et al.
	A-29	2002-0164341	11/7/2002	Davis, et al.
	A-30	2002-0165178	11/7/2002	Schetter, et al.
	A-31	2002-0183272	12/5/2002	Johnston, et al.
	A-32	2002-0197269	12/26/2002	Lingnau, et al.

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen


	A-33	2002-0198165	12/26/2002	Bratzler, et al.
	A-34	2003-0003579	1/2/2003	Kadowaki, et al.
	A-35	2003-0022849	1/30/2003	Chang
	A-36	2003-0022852	1/30/2003	Van Nest, et al.
	A-37	2003-0026782	2/6/2003	Krieg
	A-38	2003-0026801	2/6/2003	Weiner, et al.
	A-39	2003-0049266	3/13/2003	Fearon, et al.
	A-40	2003-0050261	3/13/2003	Krieg, et al.
	A-41	2003-0050263	3/13/2003	Krieg, et al.
	A-42	2003-0050268	3/13/2003	Krieg, et al.
	A-43	2003-0052839	3/20/2003	Binley, et al.
	A-44	2003-0055014	3/20/2003	Bratzler
	A-45	2003-0059773	3/27/2003	Van Nest, et al.
	A-46	2003-0060440	3/27/2003	Klinman, et al.
	A-47	2003-0064064	4/3/2003	Dina
	A-48	2003-0072762	4/17/2003	Van de Winkel, et al.
	A-49	2003-0073142	4/17/2003	Chen, et al.
	A-50	2003-0078223	4/24/2003	Raz, et al.
	A-51	2003-0091599	5/15/2003	Davis, et al.

See Boxes 2 and 3 →

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.




**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

	A-52	2003-0092663	5/15/2003	Raz
	A-53	2003-0096417	5/22/2003	Fischer
	A-54	2003-0100527	5/29/2003	Krieg, et al.
	A-55	2003-0104044	6/5/2003	Semple, et al.
	A-56	2003-0104523	6/5/2003	Lipford, et al.
	A-57	2003-0109469	6/12/2003	Carson, et al.
	A-58	2003-0119773	6/26/2003	Raz, et al.
	A-59	2003-0119774	6/26/2003	Foldvari, et al.
	A-60	2003-0119776	6/26/2003	Phillips, et al.
	A-61	2003-0125284	7/3/2003	Raz, et al.
	A-62	2003-0129251	7/10/2003	Van Nest, et al.
	A-63	2003-0130217	7/10/2003	Raz, et al.
	A-64	2003-0133988	7/17/2003	Fearon, et al.
	A-65	2003-0135875	7/17/2003	Ehrhardt, et al.
	A-66	2003-0138413	7/24/2003	Vicari, et al.
	A-67	2003-0138453	7/24/2003	O'Hagan, et al.
	A-68	2003-0139364	7/24/2003	Krieg, et al.
	A-69	2003-0143213	7/31/2003	Raz, et al.
	A-70	2003-0143743	7/31/2003	Schuler, et al.


EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

				Attorney Docket Number	4239-61997-01
				Application Number	10/068,160
				Filing Date	February 6, 2002
				First Named Inventor	Klinman
				Art Unit	1623
				Examiner Name	Dave Nguyen
	A-71	2003-0144229	7/31/2003	Klinman, et al.	
	A-73	2003-0147870	8/7/2003	Raz, et al.	
	A-74	2003-0148316	8/7/2003	Lipford, et al.	
	A-75	2003-0148976	8/7/2003	Krieg, et al.	
	A-76	2003-0148983	8/7/2003	Fontoura, et al.	
	A-77	2003-0157717	8/21/2003	Draghia-Akli	
	A-78	2003-0158136	8/21/2003	Rice, et al.	
	A-79	2003-0165478	9/4/2003	Sokoll	
	A-80	2003-0166001	9/4/2003	Lipford	
	A-81	2003-0171321	9/11/2003	Schmidt, et al.	
	A-82	2003-0170273	9/11/2003	O'Hagan, et al.	
	A-83	2003-0175731	9/18/2003	Fearon, et al.	
	A-84	2003-0176373	9/18/2003	Raz, et al.	
	A-85	2003-0176389	9/18/2003	Raz, et al.	
	A-86	2003-0180320	9/25/2003	Darju, et al.	
	A-87	2003-0181406	9/25/2003	Schetter, et al.	
	A-88	2003-0185848	10/2/2003	Johnston, et al.	
	A-89	2003-0185900	10/2/2003	Choi, et al.	
	A-90	2003-0186921	10/2/2003	Carson, et al.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



OCT 15 2004

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

	A-91	2003-0191079	10/9/2003	Krieg, et al.
	A-92	2003-0199466	10/23/2003	Fearon, et al.
	A-93	2003-0203861	10/30/2003	Carson, et al.
	A-94	2003-0206967	11/6/2003	Choi, et al.
	A-95	2003-0207287	11/6/2003	Short
	A-96	2003-0212026	11/13/2003	Krieg, et al.
	A-97	2003-0212028	11/13/2003	Raz, et al.
	A-98	2003-0216340	11/20/2003	Van Nest, et al.
	A-99	2003-0219752	11/27/2003	Short
	A-100	2003-0220277	11/27/2003	Yew, et al.
	A-101	2003-0224010	12/4/2003	Davis, et al.
	A-102	2003-0225016	12/4/2003	Fearon, et al.
	A-103	2003-0232780	12/18/2003	Carson, et al.
	A-104	2004-0005588	1/8/2004	Cohen, et al.
	A-105	2004-0006010	1/8/2004	Carson, et al.
	A-106	2004-0006032	1/8/2004	Lopez
	A-107	2004-0006034	1/8/2004	Raz, et al.
	A-108	2004-0009897	1/15/2004	Sokoll
	A-109	2004-0009942	1/15/2004	Van Nest

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

	A-110	2004-0009949	1/15/2004	Krieg
	A-111	2004-0013686	1/22/2004	Granoff, et al.
	A-112	2004-0013688	1/22/2004	Wise, et al.
	A-113	2004-0028693	2/12/2004	Wu, et al.


FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
	F-1	EPO	EP 0 092 574	4/29/1992	
	F-2	EPO	EP 0 286 224	10/12/1988	
	F-3	EPO	EP 0 302 758	11/8/1989	
	F-7	EPO	EP 1 198 249	4/24/2002	
	F-8	WIPO	WO 00/06588	10/20/2000	
	F-9	WIPO	WO 00/14217	3/16/2000	
	F-10	WIPO	WO 00/20039	4/13/2000	
	F-11	WIPO	WO 00/21556	4/20/2000	
	F-12	WIPO	WO 00/61151	10/19/2000	
	F-13	WIPO	WO 00/62787	10/26/2000	
	F-14	WIPO	WO 00/67023	11/9/2000	
	F-15	WIPO	WO 00/67787	11/16/2000	
	F-16	WIPO	WO 01/00232	1/4/2001	

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

	F-17	WIPO	WO 01/02007	1/11/2001	
	F-18	WIPO	WO 01/12223	2/22/2001	
	F-19	WIPO	WO 01/12804	2/22/2001	
	F-20	WIPO	WO 01/22990	4/5/2001	
	F-21	WIPO	WO 01/51500	7/19/2001	
	F-22	WIPO	WO 01/55341	8/2/2001	
	F-23	WIPO	WO 01/68077	9/20/2001	
	F-24	WIPO	WO 01/68103	9/20/2001	
	F-25	WIPO	WO 01/68116	9/20/2001	
	F-26	WIPO	WO 01/68117	9/20/2001	
	F-27	WIPO	WO 02/69369	9/6/2002	
	F-28	WIPO	WO 91/12811	9/5/1991	
	F-29	WIPO	WO 92/03456	4/5/1992	
	F-30	WIPO	WO 92/18522	10/29/1992	
	F-31	WIPO	WO 92/21353	12/10/1992	
	F-33	WIPO	WO 94/19945	9/15/1994	
	F-34	WIPO	WO 95/05853	3/2/1995	
	F-38	WIPO	WO 96/24380	2/5/1996	
	F-39	WIPO	WO 96/35782	11/14/1996	

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

	F-40	WIPO	WO 97/28259	1/28/1997	
	F-42	WIPO	WO 98/14210	4/9/1998	
	F-43	WIPO	WO 98/16247	4/23/1998	
	F-45	WIPO	WO 98/29430	12/19/1997	
	F-46	WIPO	WO 98/32462	7/30/1998	
	F-50	WIPO	WO 98/49348	11/5/1998	
	F-51	WIPO	WO 98/52581	11/26/1998	
	F-53	WIPO	WO 99/11275	3/11/1999	
	F-54	WIPO	WO 99/37151	7/29/1999	

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
	1	ADYA, et al., "Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB". Proc. Natl. Acad. Sci. USA 91(12):5642-5646 (1994).
	2	AGRAWAL, et al., "Pharmacokinetics of Oligonucleotides". Ciba. Found. Symp. 209:60-78 (1997), abstract only.
	3	AGRAWAL, et al., "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administration of Experimental Animals". Handb. Exp. Pharmacol.: Antisense Research and Application 131:525-543 (1998).
	4	AGRAWAL, "Antisense Oligonucleotides: Toward Clinical Trials". Tibtech 14:376-387 (1996).
	5	AGRAWAL, et al., "In Vivo Pharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous Guanosines". Antisense & Nucleic Acid Drug Development 7:245-249 (1997).
	6	AGRAWAL, et al., "Absorption, Tissue Distribution and In Vivo Stability in Rats of a Hybrid Antisense Oligonucleotide Following Oral Administration". Biochemical Pharmacology 50(4):571-576 (1995).
	7	AGRAWAL, et al., "Pharmacokinetics of Antisense Oligonucleotides". Clin. Pharmacokinet 28(1):7 (1995).
	8	AGRAWAL, et al., "Antisense therapeutics: is it as simple as complementary base recognition?". Molecular Med. Today 6(2):72-81 (2000), abstract only.

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

9	AGRAWAL, et al., "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice". Proc. Natl. Acad. Sci. USA 88:7595-7599 (1991).
10	AGRAWAL, "Medicinal Chemistry and Therapeutic Potential of CpG DNA". Trends in Molecular Medicine 8(3):114-121 (2002).
12	AMARAL, et al., "Leishmania amazonensis: The asian rhesus macaques (Macaca mulatta) as an experimental model for study of cutaneous leishmaniasis". Exp. Parasitol. 82(1):34-44 (1996).
13	ANDERSON, "Human Gene Therapy". Nature 392:25-30 (Apr. 1998).
14	ANDERSON, et al., "TH2 and 'TH2-like' cells in allergy and asthma; pharmacological perspectives". TiPS 15:324-332 (1994).
15	ANFOSSI, et al., "An oligomer complementary to c-myc-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines". Proc. Natl. Acad. Sci. USA 86:3379-3383 (May 1989).
16	ANGIER, "Microbe DNA seen as alien by immune system". New York Times Page C1, 2 pages (1995).
17	AZAD, et al., "Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region". Antimicrobial Agents and Chemotherapy 37:1945-1954 (1993).
18	AZUMA, "Biochemical and immunological studies on cellular components of tubercle bacilli". Kekkaku 69(9):45-55 (1992).
19	AZZONI, et al., "Sustained Impairment of IFN- γ Secretion in Suppressed HIV-Infected Patients Despite Mature NK Cell Recovery: Evidence for a Defective Reconstruction of Innate Immunity". J. Immunol. 168(11):5764-5770 (2002).
21	BANCHEREAU, et al., "Immunobiology of Dendritic Cells". Ann. Rev. Immunol. 18:767-811 (2000).
22	BANCHEREAU & STEINMAN, "Dendritic Cells and the Control of Immunity". Nature 392:245-252 (1998).
23	BAROUCH, et al., "Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination". Science 290:486-492 (Oct. 2000).
24	BAUER, et al., "Bacterial CpG-DNA Triggers Activation and Maturation of Human CD11c-, CD123+ Dendritic Cells". J. Immunol. 166:5000-5007 (2001).
25	BAYEVER, "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial". Antisense Res. Dev. 3:383-390 (1993).
26	BENIMETSKAYA, et al., "Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kBp65) 'antisense' oligodeoxynucleotide". Nucleic Acids Research 25(13):2648-2656 (1997).
27	BENNETT, et al., "DNA binding to human leukocytes: evidence for a receptor-mediated association, internalization, and degradation of DNA". J. Clin. Invest. 76(6):2182-2190 (1985).
28	BERG, et al., "Interleukin-10 is a central regulator for the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance". J. Clin. Invest. 96(5):2339-2347 (1995).
29	BIOLABS, "1988-1989 Catalog, Random Primer #s 1230, 1601, 1602". ().

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

30	BISHOP, et al., "Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide". The Journal of Biological Chemistry 271(10):5698-5703 (Mar.1996).
31	BLANCHARD, et al., "Interferon- γ Induction by Lipopolysaccharide: Dependence of Interleukin 2 and Macrophages". The Journal of Immunology 136(3):963-970 (Feb. 1986).
32	BLANCO, et al., "Induction of Dendritic Cell Differentiation by IFN- α in Systemic Lupus Erythematosus". Science 294:1540-1543 (2001).
33	BLAXTER, et al., "Genes expressed in Brugia malayi infective third stage larvae". Mol. Biochem. Parasitol. 77:77-93 (1996).
34	BOGGS, et al., "Characterization and modulation of immune stimulation by modified oligonucleotides". Antisense Nucl. Acid Drug Dev. 7(5):461-471 (1997).
35	BOIARKINA, et al., "Dietary supplementals from ground fish meat with DNA for treatment and prophylaxis". Vopr. Pitan 1:29-31 (1998), abstract only.
36	BRANDA, et al., "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1". Biochem. Pharmacol. 45(10):2037-2043 (1993).
37	BRANDA, et al., "Amplification of antibody production by phosphorothioate oligodeoxynucleotides". J. Lab Clin. Med. 128(3):329-338 (1996).
38	BRISKIN, et al., "Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation". Mol. Cell Bio. 10(1):422-425 (1990).
39	BURGESS, "The antiproliferative activity of c-myc and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism". Proc. Natl. Acad. Sci. USA 92:4051-4055 (Apr. 1995).
40	CALAROTA, et al., "Immune Responses in Asymptomatic HIV-1 Infected Patients After HIV-DNA Immunization Followed by Highly Active Antiretroviral Treatment". J. Immunol. 163(4):2330-2338 (1999).
41	CHACE, et al., "Regulation of differentiation in CD5+ and conventional B cells". Clin. Immunol. Immunopathol. 68(3):327-332 (1993).
42	CHANG, et al., "The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements". J. Virol. 64(1):264-277 (1990).
43	CHAPUIS, et al., "Differentiation of Human Dendritic Cells from Monocytes in vitro". Eur. J. Immunol. 27:431-441 (1997).
44	CHEHIMI, "Persistent Decreases in Blood Plasmacytoid Dendritic Cell Number and Function Despite Effective Highly Active Antiretroviral Therapy and Increased Blood Myeloid Dendritic Cells in HIV-Infected Individuals". J. Immunol. 168(9):4796-4801 (2002).
45	CHU, et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity". J. Exp. Med. 186(10):1623-1631 (1997).
46	CHUN, et al., "Effect of interleukin-2 on the pool of latently infected, resting CD4+ T-cells in HIV-1-infected patients receiving highly active anti-retroviral therapy". Nature Med. 5(6):651-655 (1999).
47	CHUN, et al., "Perspective: Latent reservoirs of HIV: Obstacles to the eradication of virus". Proc. Natl. Acad. Sci. USA 96:10958-10961 (1999).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

		Attorney Docket Number	4239-61997-01
		Application Number	10/068,160
		Filing Date	February 6, 2002
		First Named Inventor	Klinman
		Art Unit	1623
		Examiner Name	Dave Nguyen
	48	COHEN, et al., "Exploring How to Get at -- and Eradicate -- Hidden HIV". Science 279:1854-1855 (1998).	
	49	COHEN & FAUCI, et al., "HIV/AIDS in 1998 -- Gaining the Upper Hand?". JAMA 280(1):87-88 (1998).	
	50	COOK, et al., "Effect of a Single Ethanol Exposure on HIV Replication in Human Lymphocytes". J. Invest. Med. 45(5):265-271 (1997).	
	51	COOPER, et al., "Therapeutic Strategies for HIV Infection -- Time To Think Hard". The New England Journal of Medicine 339(18):1319-1321 (1998).	
	52	COWDERY, et al., "Bacterial DNA induces NKcells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides". J. Immunol. 156(12):4570-4575 (1996).	
	53	CROSBY, et al., "The early responses gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG (GSG) element-binding protein family". Mol. Cell Bio. 2:3835-3841 (1991).	
	54	CRYSTAL, "Transfer of genes to humans: early lessons and obstacles to success". Science 270:404-410 (1995).	
	55	CRYZ, et al., "Vaccine Delivery System -- European Commission COST/STD Initiative Report of the Expert Panel VII". Vaccine 14(7):665-690 (1996).	
	56	D'ANDREA, et al., "Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells". J. Exp. Med. 178(3):1041-1048 (1993).	
	57	DAVEY, et al., "HIV-1 and T-Cell dynamics after interruption of highly antiretroviral therapy (HAART) in patients with a history of sustained viral suppression". Proc. Natl. Acad. Sci. USA 96(26):15109-15114 (1999).	
	59	DAVIS, et al., "CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen". J. Immunol. 160(2):870-876 (1998).	
	60	DAVIS, "Plasmid DNA expression systems for the purpose of immunization". Curr. Opin. Biotechnol. 8(5):635-646 (Oct. 1997).	
	61	DEMATOS, et al., "Pulsing of Dendritic Cells with Cell Lysates from Either B16 Melanoma or MCA-106 Fibrosarcoma Yields Equally Effective Vaccines Against B16 Tumors in Mice". J. Surg. Oncol. 68:79-91 (1998).	
	62	DEML, et al., "Immunostimulatory CpG motifs trigger a T Helper-1 immune response to Human Immunodeficiency Virus Type-1 (HIV-1) gp160 envelope protein". Clin. Chem. Lab. Med. 37(3):199-204 (1999).	
	63	DIAS et al., "Minireview: Antisense Oligonucleotides: Basic Concepts and Mechanisms," <i>Mol. Can. Ther.</i> 1:347-355, 2002	
	64	DOERFLER, et al., "On the Insertion of Foreign DNA into Mammalian Genomes: Mechanism and Consequences". <i>Gene</i> 157(1-2):241-254 (1995), abstract only.	
	65	DURHAM, et al., "Immunotherapy and Allergic Inflammation". <i>Clin. Exp. Allergy</i> 21 Suppl 1:206-210 (1991).	
	66	ECK, et al., "Chapter 5: Gene-Based Therapy". Goodman & Gilman's The Pharmacological Basis of Therapeutics 9th ed.:77-101 (1996).	

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

67	ELKINS, et al., "Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria". J. Immunol. 162:2291-2298 (1999).
68	ENGLISH, et al., "Chemically modified oligonucleotides as probes and inhibitors". Angew. Chem. Int. Ed. Engl. 30:613-629 (1991).
69	ERB, et al., "Infection of mice with Mycobacterium bovis-badillus Calmette-Guerin (BCG) supresses allergen-induced airway eosinophilia". J. Exp. Med. 184(4):561-569 (1998).
70	ETLINGER, "Carrier sequence selection--one key to successful vaccines". Immunology Today 13(2):52-55 (1992).
71	FANSLOW, et al., "Effect of Nucleotide Restriction and Supplementation on Resistance to Experimental Murine Candidiasis". J. Parenter. Enteral. Nutr. 12(1):49-52 Abstract (1988).
72	FIELDS, et al., "Murine Dendritic Cells Pulsed With Whole Tumor Lysates Mediate Potent Antitumor Immune Responses in vitro and in vivo". Proc. Natl. Acad. Sci. USA 95:9482-9487 (1998).
73	FILION, et al., "Major Limitations in the use of Cationic Liposomes for DNA Delivery". Int. J. Pharmaceuticals 162:159-170 (1998).
74	FOX, "Mechanism of action of hydroxychloroquine as an antirheumatic drug". Chem. Abstracts 120:15, Abstract No. 182630 (1 page) (1994).
75	FREIDAG, et al., "CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis". Infect. Immun. 68:2948-2953 (2000).
76	GAO, et al., "Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and Rnase H: Implications for antisense technology". Mol. Pharmacol. 41:223-229 (1992).
77	GARRAUD, "Regulation of Immunoglobulin Production in Hyper-IgE (Job's) Syndrome". J. Allergy Clin. Immunol. 103(2 Pt 1):333-340 (Feb. 1999).
78	GLUCKMAN, et al., "In Vitro Generation of Human Dendritic Cells and Cell Therapy". Cytokines Cell Mol. Ther. 3:187-196 (1997).
79	GRAMZINSKI, et al., "Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice". Infect. Immun. 69(3):1643-1649 (2001).
80	GURA, "Antisense has growing pains". Science 270:575-576 (1995).
81	GURSEL, "Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides". J. Immunol. 167(6):3324-3328 (2001).
82	GURSEL, et al., "Differential and Competitive Activation of Human Immune Cells by Distinct Classes of CpG Oligodeoxynucleotide". J. Leuko. Biol. 71:813-820 (2002).
83	HADDEN, et al., "Immunopharmacology". JAMA 268(20):2964-2969 (1992).
84	HADDEN, et al., "Immunostimulants". TIPS 141:169-174 (1993).
85	HALPERN, et al., "Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha". Cell Immunol. 167(1):72-78 (1996).
86	HASLETT, et al., "Strong Human Immunodeficiency Virus (HIV) Specific CD4+ T Cell Responses in a Cohort of Chronically Infected Patients are Associated with Interruptions in Anti-HIV Chemotherapy". J. Infect. Diseases 181:1264-1272 (2000).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

87	HATZFELD, "Release of early human hematopoietic progenitors from quiescence by antisense transformin growth factor β 1 or Rb oligonucleotides". J. Exp. Med. 174:925-929 (1991).
88	HAVLIR, et al., "Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug Therapy". The New England Journal of Medicine 339(18):1261-1268 (1998).
89	HAYASHI, et al., "Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase". Infect. Immun. 69:6156-6164 (2001).
90	HERTL, et al., "Inhibition of Interferon- γ -Induced Intercellular Adhesion Molecule-1 Expression on Human Keratinocytes by Phosphorothioate Antisense Oligodeoxynucleotides is the Consequence of Antisense-Specific and Antisense-Non-Specific Effects". The Journal of Investigative Dermatology 104(5):813-818 (May 1995).
91	HIGHFIELD, "Sepsis: the more, the murkier". Biotechnology 12:828 (1994).
92	HOEFFLER, et al., "Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions". Mol. Endocrinol. 5(2):256-266 (1991).
93	HONESS, et al., "Deviations from Expected Frequencies of CpG Dinucleotides in Herpesvirus DNAs May be Diagnostic of Differences in the States of Their Latent Genomes". J. Gen. Vir. 70(4):837-855 (1989).
94	HORSPOOL, et al., "Nucleic acid vaccine-induces immune responses require CD28 costimulation and are regulated by CTLA4". J. Immunol. 160:2706-2714 (1998).
95	HUGHES, et al., "Influence of Base Composition on Membrane Binding and Cellular Uptake of 10-mer Phosphorothioate Oligonucleotides in Chinese Hamster Ovary (CHRC5) Cells". Antisense Research and Development 4:211-215 (1994).
96	IGUCHI-ARIGA, et al., "CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation". Genes Dev. 3(5):612-619 (1989).
97	IMAMI, et al., "Assessment of Type 1 and Type 2 Cytokines in HIV Type 1-Infected Individuals: Impact of Highly Active Antiretroviral Therapy". AIDS Research and Human Retroviruses 15(17):1499-1508 (1999).
98	ISHIBASHI, et al., "Sp1 Decoy Transfected to Carcinoma Cells Suppresses the Expression of Vascular Endothelial Growth Factor, Transforming Growth Factor β , and Tissue Factor and Also Cell Growth and Invasion Activities". Cancer Research 60:6531-6536 (2000).
99	ISHIKAWA, et al., "IFN induction and associated changes in splenic leukocyte distribution". J. Immunol. 150(9):3713-3727 (1993).
100	IVERSEN, et al., "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion". Antisense Res. Dev. 4:43-52 (1994).
101	JAKWAY, et al., "Growth regulation of the B lymphoma cell line WEHI-23 1 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products". J. Immunol. 137(7):2225-2231 (1996).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:


* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

		Attorney Docket Number	4239-61997-01
		Application Number	10/068,160
		Filing Date	February 6, 2002
		First Named Inventor	Klinman
		Art Unit	1623
		Examiner Name	Dave Nguyen
	102	JAROSZEWSKI, et al., "Cellular uptake of antisense oligonucleotides". Adv. Drug Delivery Rev. 6(3):235-250 (1991).	
	103	JILEK, et al., "Antigen-Independent Suppression of the Allergic Immune Response to Bee Venom Phospholipase A2 by DNA Vaccination in CBA/J Mice". J. Immunol. 166:3612-3621 (2001).	
	104	JONES, et al., "Synthetic Oligonucleotides Containing CpG Motifs Enhance Immunogenicity of a Peptide Malaria Vaccine in Aotus Monkeys". Vaccine 17:3065-3071 (1999).	
	105	JUFFERMANS, et al., "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis". Infect. Immun. 70:147-152 (2002).	
	106	KADOWAKI, et al., "Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double Stranded RNA, Respectively, Stimulate CD11c- Type 2 Dendritic Cell Precursors and CD11c+ Dendritic cells to Produce Type I IFN". J. Immunol. 166:2291-2295 (2001).	
	107	KATAOKA, et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG". Jpn. J. Cancer Res. 83:244-247 (1992).	
	108	KENNEY, et al., "Protective Immunity Using Recombinant Human IL-12 and Alum as Adjuvants in a Primate Model of Cutaneous Leishmaniasis". J. Immunol. 163(8):4481-4488 (1999).	
	109	KHALED, et al., "Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides". Nucleic Acids Research 24(4):737-745 (1996).	
	110	KIMURA, et al., "Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN". J. Biochem 116(5):991-994 (1994).	
	111	KLINE, et al., "CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma". J. Invest. Med. 44(7):380A (1 page) (1996).	
	112	KLINE, et al., "CpG oligonucleotides can reverse as well as prevent TH2-mediated inflammation in a murine model of asthma". J. Invest. Med. 45(7):298A (1 page) (1997).	
	113	KLINE, et al., "Immune redirection by CpG oligonucleotides, Conversion of a Th2 response to a Th1 response in a murine model of asthma". J. Invest. Med. 45(3):282A (1 page) (1997).	
	114	KLINMAN, et al., "Immune recognition of foreign DNA: a cure for bioterrorism?". Immunity 11:123 (1 page) (1999).	
	115	KLINMAN, et al., "Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection". Infect. Immun. 67:5658-5663 (1999).	
	116	KLINMAN, et al., "Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety". Springer Semin. Immunopathol. 22:173-183 (2000).	
	117	KOU, et al., "Analysis and Regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma". Arerugi 43(3):483-491 (1994), abstract only.	
	118	KRIEG, et al., "CpG motifs in bacterial DNA and their immune effect". Annu. Rev. Immunol. 20:709-760 (2002).	
	119	KRIEG, et al., "Brief Communication: Oligodeoxynucleotide Modifications Determine the Magnitude of B-Cell Stimulation by CpG Motifs". Antisense & Nucleic Acid Drug Development 6:133-139 (1996).	


EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

			Attorney Docket Number	4239-61997-01
			Application Number	10/068,160
			Filing Date	February 6, 2002
			First Named Inventor	Klinman
			Art Unit	1623
			Examiner Name	Dave Nguyen
	120	KRIEG, et al., "Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?". Antisense Res. Dev. 5:241 (1 page) (1995).		
	121	KRIEG, et al., "Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible". Antisense Res. Dev. 1(2):161-171 (1991).		
	122	KRIEG, et al., "Leukocyte stimulation by oligodeoxynucleotides". Applied Antisense Oligonucleotide Tech. (BOOK):431-448 (1998).		
	123	KRIEG, et al., "Causing a Commotion in the Blood: Immunotherapy Progresses from Bacteria to Bacterial DNA". Immunology Today 21(10):521-526 (2000).		
	124	KRIEG, et al., "CpG DNA: A pathogenic factor in systemic lupus erythematosus?". J. Clin. Immunol. 15(6):284-292 (1995).		
	125	KRIEG, et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge". J. Immunol. 161:2428-2434 (1998).		
	126	KRIEG, et al., "A role for endogenous retroviral sequences in the regulation of lymphocyte activation". J. Immunol. 143(8):2448-2451 (1989).		
	127	KRIEG, "An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA". J. Lab. Clin. Med. 128(2):128-133 (Abstract) (1996).		
	128	KRIEG, et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy". Proc. Natl. Acad. Sci. USA 90:1048-1052 (1993).		
	129	KRIEG, et al., "The role of CpG dinucleotides in DNA vaccines". Trends in Microbiol. 6:23-27 (1998).		
	130	KRIEGER, et al., "Structures and Functions of Multiligand Lipoprotein Receptors: Macrophage Scavenger Receptors and LDL Receptor-Related Protein (LRP)". Annu. Rev. Biochem 63:601-637 (1994).		
	131	KRUG, et al., "Identification of CpG Oligonucleotide Sequences with High Induction of IFN- α/β in Plasmacytoid Dendritic Cells". Eur. J. Immunol. 31:2154-2163 (2001).		
	132	KRUG, et al., "Toll-like Receptor Expression Reveals CpG DNA as a Unique Microbial Stimulus for Plasmacytoid Dendritic Cells Which Synergizes With CD40 Ligand to Induce High Amounts of IL-12". Eur. J. Immunol. 31:3026-3037 (2001).		
	133	KUCHAN, et al., "Nucleotides in Infant Nutrition: Effects of Immune Function". Pediatr. Adolesc. Med. Basel. Karger 8:80-94 (1998).		
	134	KULKARNI, et al., "Effect of Dietary Nucleotides on Response to Bacterial Infection". J. Parenter. Enteral. Nutr. 10(2):169-171 Abstract (1986).		
	135	KURAMOTO, et al., "Oligonucleotide sequences required for natural killer cell activation". Jpn. J. Cancer Res. 83:1128-1131 (1992).		
	136	LAGRANGE, et al., "Immune Responses Directed Against Infectious and Parasitic Agents". Immunology (BOOK - ISBN:0471017604) (Chapter of Book; Ed - Jean-François Bach): (1978).		
	137	LANG, et al., "Guanosine-rich oligodeoxynucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells". Eur. J. Immunol. 29:3496-3506 (1999).		

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

138	LAPATSCHEK, et al., "Activation of Macrophages and B Lymphocytes by an Oligodeoxynucleotide Derived from an Acutely Pathogenic Simian Immunodeficiency Virus". Antisense Nucleic Acid Drug Dev. 8(5):357-370 (Oct. 1998).
139	LEDERGERBER, et al., "Clinical Progression and Virological Failure on Highly Active Antiretroviral Therapy in HIV-1 Patients: a Prospective Cohort Study". The Lancet 353:863-868 (1999).
140	LEDERMAN, et al., "Polydeoxyguanine Motifs in a 12-mer Phosphorothioate Oligodeoxynucleotide Augment Binding to the v3 Loop of the HIV-1 gp120 and Potency of HIV-1 Inhibition Independently of G-Tetrad Formation". Antisense & Nucleic Acid Drug Development 6:281-289 (1996).
141	LEE, et al., "An Oligonucleotide Blocks Interferon- γ Signal Transduction". Transplantation 62(9):1297-1301 (1996).
142	LEIBSON, et al., "Role of γ -interferon in antibody-producing responses". Nature 309:799-801 (1984).
143	LEONARD, et al., "Conformation of guanine 8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(O8A)GCG)". Biochemistry 31(36):8415-8420 (1992).
144	LI, et al., "Long-Lasting Recovery in CDR T-Cell Function and Viral -Load Reduction After Highly Active Antiretroviral Therapy in Advanced HIV-1 Disease". The Lancet 351:1682-1686 (1998).
145	LIPFORD, et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants". Eur. J. Immunol. 27(9):2340-2344 (1997).
146	LIPFORD, et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines". Eur. J. Immunol. 27(12):3420-3426 (1997).
147	MACAYA, et al., "Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution". Proc. Natl. Acad. Sci. USA 90:3745-3749 (Apr.1993).
148	MACFARLANE, et al., "Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds". J. Immunol. 160(3):1122-1131 (1998).
149	MADDON, "The Isolation and Nucleotide Sequence of a cDNA Encoding the T Cell Surface Protein T4: A New Member of the Immunoglobulin Gene Family". Cell 42(1):93-104 (1985).
150	MALTESE, et al., "Sequence context of antisense RelA/NF- κ B phosphorothioates determines specificity". Nucleic Acids Research 23(7):1146-1151 (1995).
151	MANZEL, et al., "Lack of Immune Stimulation by Immobilized CpG-oligonucleotide". Antisense & Nucleic Acid Drug Development 9(5):459-464 (1999).
152	MASTRANGELO, et al., "Gene therapy for human cancer: an essay for clinicians". Seminars Oncology 23(1):4-21 (1996).
153	MATSON, et al., "Nonspecific suppression of [3H]thymidine incorporation by control oligonucleotides". Antisense Res. Dev. 2(4):325-330 (1992).
154	MCCLUSKIE, et al., "Route and Method of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates". Molecular Med. 5(5):287-300 (1999).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

155	MCINTYRE, et al., "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation". Antisense Res. Dev. 3(4):309-322 (1993).
156	MCKENZIE, "Nucleic Acid Vaccines". Immunologic Res. 24(3):225-244 (2001).
157	MERAD, et al., "In vivo Manipulation of Dendritic Cells to Induce Therapeutic Immunity". Blood 99(5):1676-1682 (2002).
158	MESSINA, et al., "Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA". Cell Immunol. 147(6):1759-1764 (1991).
159	MESSINA, et al., "The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens". J. Immunol. 147:148-157 (1993).
160	MOJCIK, et al., "Administration of a phosphorothioate oligonucleotide antisense murine endogenous retroviral MCF env causes immune effect in vivo in a sequence-specific manner". Clin. Immunol. Immunopathol. 67(2):130-136 (1993).
161	MOSS & LEDMAN, "Immunization of the Immunocompromised Host". Clinical Focus on Primary Immune Deficiencies 1(1):1-3 (1998).
170	MOTTRAM, et al., "A novel CDC2-related protein kinase from leishmania mexicana, LmmCRK1, is post-translationally regulated during the life cycle". J. Biol. Chem. 268(28):21044-21052 (1993).
171	NYCE, et al., "DNA antisense therapy for asthma in an animal model". Nature 385:721-725 (1997).
172	OGG, et al., "Quantitation of HIV-1-Specific Cytotoxic T-Lymphocytes and Plasma Load of Viral RNA". Science 279:2103-2106 (1998).
173	OKADA, et al., "Bone Marrow-Derived Dendritic Cells Pulsed With a Tumor-Specific Peptide Elicit Effective Anti-Tumor Immunity Against Intracranial Neoplasms". Int. J. Cancer 78:196-201 (1998).
174	PALUCKA, et al., "Dendritic Cells as the Terminal Stage of Monocyte Differentiation". J. Immunol. 160:4587-4595 (1999).
175	PAPASAVVAS, et al., "Enhancement of Human Immunodeficiency Virus Type I-Specific CD4 and CD8 T Cell Responses in Chronically Infected Persons after Temporary Treatment Interruption". J. Infect. Diseases 182:766-775 (2000).
176	PIALOUX, et al., "A Randomized Trial of Three Maintenance Regimens Given After Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1-Infected Patients". The New England Journal of Medicine 339(18):1269-1276 (1998).
177	PISCITELLI, "Immune-Based Therapies for Treatment of HIV Infection". The Annals of Pharmacotherapy 30:62-76 (1996).
178	PISETSKY, et al., "Immunological Properties of Bacterial DNA". Ann. NY Acad. Sci. 772:152-163 (1995).
179	PISETSKY, "Immunological consequences of nucleic acid therapy". Antisense Res. Dev. 5:219-225 (1995).
180	PISETSKY, "The immunological properties of DNA". J. Immunol. 156:421-423 (1996).
181	PISETSKY, et al., "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus". Life Science 54:101-107 (1994), abstract only.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

182	PISETSKY, "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides". Molecular Biol. Reports 18:217-221 (1993).
183	PLENAT, "Animal models of antisense oligonucleotides: lessons for use in humans". J. Mol. Med. Today 2(6):250-257 (1996).
184	PRASAD, et al., "Oligonucleotides Tethered to a Short Polyguanylic Acid Stretch are Targeted to Macrophages: Enhanced Antiviral Activity of a Vesicular Stomatitis Virus-Specific Antisense Oligonucleotide". Antimicrobial Agents and Chemotherapy 43(11):2689-2696 (Nov. 1999).
185	QUDDUS, et al., "Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice". J. Clin. Invest. 92(1):38-53 (1993).
186	RAMANATHAN, et al., "Characterization of the Oligodeoxynucleotide-mediated Inhibition of Interferon- γ -induced Major Histocompatibility Complex Class I and Intercellular Adhesion Molecule-1". The Journal of Biological Chemistry 269(40):24564-24574 (Oct. 1994).
187	RAMANATHAN, et al., "Inhibition of Interferon- γ -Induced Major Histocompatibility Complex Class I Expression by Certain Oligodeoxynucleotides". Transplantation 57(4):612-615 (Feb. 1994).
188	RAZ, "Deviation of the Allergic IgE to an IgG Response by Gene Immunotherapy". Int. Rev. Immunol. 18(3):271-289 (1999).
189	RAZ, et al., "Preferential Induction of a Th1 Immune Response and Inhibition of Specific IgE Antibody Formation by Plasmid DNA Immunization". Proc. Natl. Acad. Sci. USA 93:5141-5145 (1996).
190	RAZ, et al., "Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses". Proc. Natl. Acad. Sci. USA 91:9519-9523 (1994).
191	RICCI, et al., "T cells, cytokines, IgE and allergic airways inflammation". J. Invest. Allergol Clin. Immunol. 4(5):214-220 (1994).
192	ROJANASAKUL, "Antisense oligonucleotide therapeutics: drug delivery and targeting". Drug Delivery Reviews 18:115-131 (1996).
193	ROMAN, et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants". Nature Med. 3(8):849-854 (1997).
194	ROSENBERG, et al., "Immune Control of HIV-1 After Early Treatment of Acute Infection". Nature 407:523-526 (2000).
195	ROSENBERG, et al., "Vigorous HIV-1-Specific CD4+ T-Cell Responses Associated with Control of Viremia". Science 278:1447-1450 (1997).
196	RUIZ, et al., "Structured Treatment Interruption in Chronically HIV-1 Infected Patients After Long-Term Viral Suppression". AIDS 14:397-403 (2000).
197	SANTINI, et al., "Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vitro and in Hu-PBL-SCID Mice". J. Exp. Med. 191:1777-1788 (2000).
198	SATO, et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization". Science 273:352-354 (1996).
199	SCHNELL, et al., "Identification and characterization of a Saccharomyces cerevisiae gene (PAR 1) conferring resistance to iron chelators". Eur. J. Biochem. 200:487-493 (1991).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

200	SCHOOFS, "Small Steps -- A Limited Experiment Opens New Approach in Fight Against HIV". Wall Street Journal (Sep. 28, 2000).
201	SCHUBBERT, et al., "Ingested Foreign (phage M13) DNA Survives Transiently in the Gastrointestinal Tract and Enters the Bloodstream of Mice". Mol. Gen. Genet. 242:495-504 (1994).
202	SCHWARTZ, et al., "Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract". Am. J. Physiol. 267(5):609-617 (1994).
203	SCHWARTZ, et al., "The role of endotoxin in grain dust-induced lung disease". Am. J. Respir. Crit. Care Med. 152(2):603-608 (1995).
204	SCHWARTZ, et al., "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract". J. Clin. Invest. 100(1):68-73 (1997).
205	SEDEGAH, et al., "Intertukin 12 induction of interferon g-dependent protection against malaria". Proc. Natl. Acad. Sci. USA 91:10700-10792 (1994).
206	SETHI, et al., "Postexposure prophylaxis against prion disease with a stimulator of innate immunity". Lancet 360:229-230 (2002).
207	SHAFFER, et al., "Highly Active Antiretroviral Therapy (HAART) for the Treatment of Infection With Human Immunodeficiency Virus Type 1". Biomed. & Pharmacother. 53:73-86 (1999).
208	SHIRAKAWA, et al., "The inverse association between tuberculin responses and atopic disorder". Science 275(5296):77-79 (1997).
209	SIDMAN, et al., "γ-Interferon is one of several direct B cell-maturing lymphokines". Nature 309:801-804 (1984).
210	SPARWASSER, et al., "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-α-mediated shock". Eur. J. Immunol. 27(7):1671-1679 (1997).
211	SPARWASSER, et al., "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells". Eur. J. Immunol. 28:2045-2054 (1998).
212	SPIEGELBERG, et al., "Recognition of T Cell Epitopes and Lymphokine Secretion by Rye Grass Allergen Lolium perenne I-Specific Human T Cell Clones". J. of Immunology 152:4706-4711 (1994).
213	STACEY, et al., "Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major". Infect. Immun. 67:3719-3726 (1999).
214	STEIN, et al., "Oligodeoxynucleotides as inhibitors of gene expression: a review". Cancer Res. 48:2659-2668 (1998).
215	STULL, et al., "Antigene, ribozyme, and aptamer nucleic acid drugs: progress and prospects". Pharm. Res. 12(4):465-483 (1995).
216	SU, et al., "Vaccination against Chlamydial Genital Tract Infection after Immunization with Dendritic Cells Pulsed Ex Vivo with Nonviable Chlamydiae". J. Exp. Med. 188:809-818 (1998).
217	SUBRAMANIAN, et al., "Theoretical considerations on the 'spine of hydration' in the minor groove of d(CGCGAATTCGCG) d(CGGCTTAAGCGC): Monte Carlo computer simulation". Proc. Natl. Acad. Sci. USA 85:1836-1840 (1988).
218	SYME, et al., "Generation of Dendritic Cells ex vivo: Differences in Steady State versus Mobilized Blood from Patients with Breast Cancer, with Lymphoma, and from Normal Donors". J. Hematother. Stem Cell Res. 10:621-630 (2001).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

219	TANAKA, et al., "An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germhine transcripts, stimulates B cell DNA synthesis and inhibits immunoglobulin secretion". J. Exp. Med. 175:597-607 (1992).
220	TARTE, et al., "Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro". Leukemia 14:2182-2192 (2000).
221	THORNE, "Experimental grain dust atmospheres generated by wet and dry aerosolization techniques". Am. J. Ind. Med. 25(1):109-112 (1994).
222	TIGHE, et al., "Conjunction of Protein to Immunostimulatory DNA results in a Rapid Long-Lasting and Potent Induction of Cell-Mediated and Humoral Immunity". Eur. J. Immunol. 30:1939-1947 (2000).
223	TOKUNAGA, et al., "A synthetic single-stranded DNA, poly(dG, dC), induces interferon- α/β and - γ , augments natural killer activity and suppresses tumor growth". Jpn. J. Cancer Res. 79:682-686 (1988).
224	TOKUNAGA, et al., "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells". Microbiol. Immunol. 36(1):55-66 (1992).
225	UHLMANN, et al., "Antisense oligonucleotides: a new therapeutic principle". Chem. Rev. 90:543-584 (1990).
226	VERDIJK, et al., "Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) Induces Stable Maturation of Functionally Active Human Dendritic Cells". J. Immunol. 163:57-61 (1999).
227	VERMA, et al., "Gene therapy - promises, problems and prospects". Nature 389:239-242 (Sep.1997).
228	VERTHELYI, et al., "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs". J. Immunol. 166:2372-2377 (2001).
229	VERTHELYI, et al., "CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates". J. Immunol. 168:1659-1663 (2002).
230	VIL'NER, "Effect of Amphotericin B on the interferonogenic activity of poly(G).poly (C) and poly(G,I).poly(C) in mice and their resistance to infection by the tick-borne encephalitis virus". Antibiotiki 27(11):827-830 (Nov. 1982), abstract.
231	VIL'NER, et al., "Effect of virazole on the antiviral activity of poly(G) X poly© and other polyribonucleotide interferogens". Antibiotiki 29(6):450-453 (1984), abstract.
232	VIL'NER, et al., "Evaluation of the size of the continuous poly(G) site necessary for the biological activity of the poly(G).poly(C) complex". Vopr Virusol 30(3):337-340 (1985), abstract.
233	VIL'NER, "Effect of the size of the continuous poly(G) site in poly(G,A).poly(C) complexes on their interferon-inducing activity and their capacity to stimulate the development of the immunity". Vopr Virusol 31(6):697-700 (1986), abstract.
234	VIL'NER, et al., "Dependence of the antiviral activity of the poly(G).poly(C) complex on the size of the continuous poly(C) segments". Vopr Virusol 33(3):331-335 (1988), abstract.
235	WAGNER, "Bacterial CpG DNA Activates Immune Cells to Signal Infectious Danger". Adv. Immunol. 73:329-368 (1999).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.




**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

236	WAGNER, "Gene inhibition using antisense oligodeoxynucleotides". Nature 372:333-335 (1994).
237	WALKER, et al., "Activated T Cells and Cytokines in Bronchoalveolar Lavages from Patients with Various Lung Diseases Associated with Eosinophilia". Am. J. Respir. Crit. Care Med. 150:1038-1048 (1994).
238	WALKER, et al., "Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-g-dependent mechanisms". Proc. Natl. Acad. Sci. USA 96:6970-6975 (1999).
239	WALLACE, et al., "Oligonucleotide probes for the screening of recombinant DNA libraries". Methods Enzymol. 152:432-442 (1987).
240	WEINER, "The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides". Leukocyte Bio. 68:455-463 (2000).
241	WEINER, et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization". Proc. Natl. Acad. Sci. USA 94:10833-10837 (1997).
242	WEISS, "Upping the antisense ante: scientists bet on profits from reverse genetics". Science 139:108-109 (1991).
243	WHALEN, et al., "DNA-Mediated Immunization to the Helatitis B Surface Antigen: Activation and Entrainment of the Immune Response". Ann. NY Acad. Sci. 772:64-76 (1995).
244	WHALEN, "DNA vaccines for emerging infection diseases: what if?". Emerg. Infect. Dis. 2(3):168-175 (1996).
245	WLOCH, et al., "The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors". Hum. Gene Ther. 9(10):1439-1447 (Jul. 1998).
246	WOOLRIDGE, et al., "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma". Blood 89:2994-2998 (1997).
247	WU, et al., "Receptor-mediated gene delivery and expression in vivo". J. Biol. Chem. 263:14621-14624 (1988).
248	WU-PONG, "Oligonucleotides: opportunities for drug therapy and research". Pharmaceutical Tech. 18:102-114 (1994).
249	WYATT, et al., "Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion". Proc. Natl. Acad. Sci. USA 91:1356-1360 (Feb. 1994).
250	YAMAMOTO, et al., "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length". Antisense Res. Dev. 4:119-123 (1994).
251	YAMAMOTO, "Unique palindromic sequences in synthetic oligonucleotides are required to induce inf and augment INF-mediated natural killer activity". J. Immunol. 148(12):4072-4076 (1992).
252	YAMAMOTO, et al., "In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG". Jpn. J. Cancer Res. 79:866-873 (1988).

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61997-01
Application Number	10/068,160
Filing Date	February 6, 2002
First Named Inventor	Klinman
Art Unit	1623
Examiner Name	Dave Nguyen

253	YAMAMOTO, et al., "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro". Jpn. J. Cancer Res. 85:775-779 (1994).
254	YAMAMOTO, et al., "Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BeG". Kekkaku 69(9):29-32 (1994).
255	YAMAMOTO, et al., "DNA from bacteria, but not vertebrates, induces interferons, activates natural killer cells, and inhibits tumor growth". Microbiol. Immunol. 36(9):983-997 (1992).
256	YAMAMOTO, et al., "Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence AACGTT to murine splenocytes enhances interferon production and natural killer activity". Microbiol. Immunol. 38(10):831-836 (1994).
257	YASWEN, et al., "Effects of Sequence of Thioated Oligonucleotides on Cultured Human Mammary Epithelial Cells". Antisense Research and Development 3:67-77 (1993).
258	YEW, et al., "Contribution of Plasmid DNA to Inflammation in the Lung After Administration of Cationic Lipid: pDNA Complexes". Hum. Gene Ther. 10(2):223-234 (1999).
259	YI, et al., "IFN- γ promotes IL-6 and 1gM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides". J. Immunol. 156:558-564 (1996).
260	ZELPHATI, et al., "Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes". Antisense Res. Dev. 3:323 (1993).
261	ZHANG, et al., "Antigen- and Isotype-Specific Immune Responses to a Recombinant Antigen-Allergen Chimeric (RAAC) Protein". J. Immunol. 151:791-799 (1993).
262	ZHAO, et al., "Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides". Antisense Res. Dev. 3(1):53-66 (1993).
263	ZHAO, et al., "Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors". Blood 84(11):3660-3666 (1994).
264	ZHENG, et al., "Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process During the Pathogenesis of Herpetic Stromal Keratitis". J. Virol. 75(20):9828-9835 (2001).
265	ZHU, et al., "Macaque blood-derived antigen-presenting cells elicit SIV-specific immune responses". J. Med. Primatol. 29:182-192 (2000).
266	ZIMMERMANN, et al., "CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis". J. Immunol. 160:3627-3630 (1998).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.